The Elecsys NT-proBNP assay demonstrated excellent analytical performance with total imprecision of 1.5-2.5% and perfect agreement between the 2010 and 1010 instrument platforms (r=1.00).
Cross-Sectional (n=1,205)
Yes
The Elecsys NT-proBNP assay demonstrates robust analytical performance, high precision, and excellent agreement across different analyzer platforms, supporting its clinical utility.
The Elecsys NT-proBNP assay is based on two polyclonal antibodies directed at residues 1-21 and 39-50 of the NT-proBNP molecule. Analytical performance was assessed using NCCLS protocol EP-5A using three serum pools in a preliminary study then as part of a multicentre evaluation (16 instruments in 8 hospitals). Using pools of 350 pg/l, 8700 pg/l and 13000 pg/l single site within run %CV was 0.7-1.6 (1010) and 1.2-1.5 (2010) and between run CV 5.3-6.7 (1010) and 4.4-5.0 (2010). In the multicentre evaluation within run CV was 1.0-2.5% with total imprecision 1.5-2.5% and between labs imprecision 3.8-4.0%. Functional sensitivity of 50%) and no risk factors, NT-proBNP values increased with age and were higher in women than men.
Collinson et al. (Sat,) conducted a cross-sectional in Apparently healthy individuals (n=1,205). Elecsys NT-proBNP assay vs. Other instrument platforms and assays was evaluated on Analytical performance (imprecision, functional sensitivity, and agreement between platforms). The Elecsys NT-proBNP assay demonstrated excellent analytical performance with total imprecision of 1.5-2.5% and perfect agreement between the 2010 and 1010 instrument platforms (r=1.00).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: